Jun 07, 2023 / 03:30PM GMT
Chris Howerton - Jefferies - Analyst
All right, everybody. My name is Chris Howerton, part of the Jefferies biotechnology research team. Very excited to see everybody here for our healthcare conference this year and of course, to be hosting a fireside chat with one of the companies I cover, TG Therapeutics. Mike, thank you so much for joining us.
Michael Weiss - TG Therapeutics, Inc. - Chairman, President & CEO
Of course. Great to see you, Chris.
Questions and Answers:
Chris Howerton - Jefferies - AnalystLikewise. All right. So obviously, we've gotten to know each other fairly well over the last couple of years. But for those that maybe are uninitiated, what is the elevator pitch right now on TG?
Michael Weiss - TG Therapeutics, Inc. - Chairman, President & CEO
Yeah. So it doesn't have to be very long elevator ride either. So TG is a pretty straightforward company these days. We got our first drug approved in MS called BRIUMVI. That has been our focus for the
Trustpilot
